VivoSeq
Other

Keratoconjunctivitis

20

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Keratoconjunctivitis is an emerging landscape with 20 programs across 6 companies. The most active players are AKARI Therapeutics, Adenovir Pharma AB, Astellas. 7 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

40/100

Completion Rate

95/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

AKARI Therapeutics

1 program

Phase 2A

Adenovir Pharma AB

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 3AbbVie logo

AbbVie

2 programs

Phase 3V

Veloxis Pharmaceuticals

1 program

ApprovedNovartis logo

Novartis

3 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

28 of 29 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed20 · 69%
Not yet recruiting4 · 14%
Unknown status4 · 14%
Terminated1 · 3%

Clinical Trials

Trial Activity

29 trials

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Not yet recruiting·LLaboratoires Thea·Phase 2·NCT07169695·120 enrolled
3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
Not yet recruiting·TThe University of Hong Kong·Phase 3·NCT06903884·94 enrolled
Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis
Not yet recruiting·—·Phase 1·NCT06793514·32 enrolled
Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis
Not yet recruiting·SSohag University·N/A·NCT07138742·90 enrolled
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
Completed·SSecond Affiliated Hospital of Nanchang University·Phase 1·NCT05353101·48 enrolled
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
Completed·Astellas logoAstellas·Phase 3·NCT00567762·56 enrolled
Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
Completed·UUniversity Hospital, Ghent·Phase 4·NCT01211327·366 enrolled
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
Completed·AbbVie logoAbbVie·Phase 3·NCT00884585·176 enrolled
Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
Completed·LLaboratoires Thea·Phase 2·NCT01156025·16 enrolled
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Completed·IInvirsa, Inc.·Phase 2·NCT05636228·93 enrolled
Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine
Completed·MMahidol University·Phase 4·NCT01179412·172 enrolled
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
Completed·SSanten Inc.·Phase 3·NCT01751126·169 enrolled
Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Completed·JJohns Hopkins University·N/A·NCT00987467·12 enrolled
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Completed·AAdenovir Pharma AB·Phase 2·NCT01977443·47 enrolled
Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis
Completed·LLaboratoires Thea·Phase 4·NCT00357019
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)